Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion Portfolio News / Karina Tin March 26, 2024 Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion Read More »
A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors Portfolio News / Karina Tin March 25, 2024 A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors Read More »
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) Portfolio News / Karina Tin March 25, 2024 Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) Read More »
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting Portfolio News / Karina Tin March 20, 2024 Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting Read More »
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Portfolio News / Karina Tin March 18, 2024 Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Read More »
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine Portfolio News / Karina Tin March 18, 2024 Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine Read More »
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates Portfolio News / Karina Tin March 11, 2024 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates Read More »
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results Portfolio News / Karina Tin March 11, 2024 NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results Read More »
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial Portfolio News / Karina Tin March 11, 2024 Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial Read More »
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Portfolio News / Karina Tin March 7, 2024 RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Read More »
